A phase 2, open-label, multicenter study of MB-105 in patients with CD5 positive (CD5+) relapsed / refractory T-cell lymphoma (r/r TCL)
Categories (click each to see list of all clinical trials associated with that category): Cellular Therapy Support Service - CAR-T (ONC), Lymphoma/CLL (ONC)
Current Status: Open
Phase: II (Cancer Control)
Principal Investigator: Vose, Julie
Contact Information:
Sarah Snook
sarah.snook@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT06534060?term=NCT06534060&rank=1#participation-criteria
Summary
Safety Run-in
Confirm safety and tolerability of the recommended dose of MB-105 in r/r TCL in a safety run-in.
Simon Stage 1 and 2
Evaluate the anti-tumor efficacy of MB-105 in patients with r/r TCL
Secondary:
Further characterize anti-tumor efficacy of MB-105.
Assess durability of therapeutic effect.
Further characterize safety and tolerability of MB-105. Evaluate longer-term impact of MB-105 on patients with r/r TCL
Demonstrate successful manufacturing of MB-105.
Exploratory:
Investigate impacts of MB-105 CAR T on the immune system.
Assess potential of MB-105 as a "bridge to transplant" in r/r TCL